Hikma Pharmaceuticals Plc Director/PDMR Shareholding (8022J)

TIDMHIK

RNS Number : 8022J

Hikma Pharmaceuticals Plc

09 April 2015

Hikma Pharmaceuticals PLC - LTIP Awards

LONDON, 10 April 2015: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) announces that the Remuneration Committee has made the following conditional awards under the Hikma Pharmaceuticals PLC 2014 Executive Incentive Plan (the "EIP") to Persons Discharging Managerial Responsibility ("PDMR") of the Company.

Awards under the EIP were made on 10 April 2015 at a price of 1,981 pence per Ordinary Share (being the average price for the 30 day period prior to 31 December 2014, in accordance with the EIP rules) as follows:

 
      PDMR         Element B   Element C 
                     Shares      Shares 
  Bassam Kanaan     19,945      19,945 
  Michael Raya      19,655      19,655 
 Khalid Nabilsi     14,165      14,165 
  Riad Mishlawi     13,811      13,811 
  Susan Ringdal     12,012      12,012 
  Majda Labadi      10,089      10,089

The Element B share awards will be released to the participants in two years' time subject to their continued employment and the non-occurrence of forfeiture events during the vesting period as judged by the Remuneration Committee at each anniversary of the grant.

The Element C share awards will be released to the participants in three years' time subject to their continued employment.

These participants are not allowed to sell 50% of the vested shares under elements B and C until five years.

Further details on the EIP, forfeiture criteria and holding period can be found in Hikma's report and accounts for the year ended 31 December 2014 on pages 98, 103 and 104.

- ENDS -

Enquiries:

Hikma Pharmaceuticals PLC

   Peter Speirs                                                                       +44 20 7399 2760

Company Secretary

About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2014, Hikma achieved revenues of $1,489 million and profit attributable to shareholders of $278 million.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSBCGDSXBGBGUC

Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024